Showing results (1811-1820 of 3,236) with videos related to

Sort By:
Pageof 324
Biochemistry|August 29, 2009
Comparative study of two plasticins: specificity, interfacial behavior, and bactericidal activityPierre Joanne, Mélanie Falord, Olivier Chesneau, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
Leukemia|November 7, 2008
Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS studyF Lacombe, C Arnoulet, M Maynadié, et al.
Cell Reports|May 12, 2023
Vitamin K-dependent carboxylation regulates Ca2+ flux and adaptation to metabolic stress in β cellsJulie Lacombe, Kevin Guo, Jessica Bonneau, et al.
Prenatal Diagnosis|September 5, 2002
Prenatal diagnosis of female monozygotic twins discordant for Turner syndrome: implications for prenatal genetic counsellingB Gilbert, C Yardin, S Briault, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptorS Morisset, C Pilon, J Tardivel-Lacombe, et al.
Leukemia|June 1, 2002
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571R Tabrizi, F X Mahon, P Cony Makhoul, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiformeE Raymond, M Campone, R Stupp, et al.
Frontiers in Oncology|January 24, 2020
Withanolide D Enhances Radiosensitivity of Human Cancer Cells by Inhibiting DNA Damage Non-homologous End Joining Repair PathwayJerome Lacombe, Titouan Cretignier, Laetitia Meli, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development GroupC J A Punt, M J A de Jonge, S Monfardini, et al.
Pageof 324